相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Cancer statistics, 2023
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2023)
Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review
Alice Indini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Mutational Characteristics of Primary Mucosal Melanoma: A Systematic Review
Olivia Beaudoux et al.
MOLECULAR DIAGNOSIS & THERAPY (2022)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Vulvar Melanoma in association with germline MITF p.E318K variant
Diane R. Koeller et al.
CANCER GENETICS (2022)
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
Siming Li et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Evolving Treatment Approaches to Mucosal Melanoma
Shuai Zhang et al.
CURRENT ONCOLOGY REPORTS (2022)
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study
F. Dimitriou et al.
ANNALS OF ONCOLOGY (2022)
Toripalimab (anti-PD-1) versus high-dose interferon-a2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial
B. Lian et al.
ANNALS OF ONCOLOGY (2022)
Metabolic heterogeneity protects metastatic mucosal melanomas cells from ferroptosis
Weifan Lin et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2022)
Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes
Meng Wang et al.
GENOME MEDICINE (2022)
Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature
Malgorzata Chlopek et al.
MODERN PATHOLOGY (2022)
mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model
Chutamath Sittplangkoon et al.
FRONTIERS IN IMMUNOLOGY (2022)
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
Joel Ho et al.
FRONTIERS IN ONCOLOGY (2022)
Development of therapeutic vaccines for the treatment of diseases
Yaomei Tian et al.
MOLECULAR BIOMEDICINE (2022)
Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma
Alexander N. Shoushtari
JOURNAL OF CLINICAL ONCOLOGY (2021)
Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma
Xieqiao Yan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma
Natasa Broit et al.
MOLECULAR CANCER RESEARCH (2021)
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
Yousef Zakharia et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas
Joanna P. Wroblewska et al.
CELLS (2021)
The mutational landscape of mucosal melanoma
Kelsey W. Nassar et al.
SEMINARS IN CANCER BIOLOGY (2020)
The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway
David E. Elder et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2020)
Significance of 5-S-Cysteinyldopa as a Marker for Melanoma
Kazumasa Wakamatsu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.
Xinan Sheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Primary malignant melanoma of the esophagus with multiple lymph node metastases A case report and literature review
Kenichi Iwasaki et al.
MEDICINE (2020)
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Nicholas D. Klemen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Molecular Profiling of Advanced Malignancies: A Community Oncology Network Experience and Review of Literature
Pritam Tayshetye et al.
FRONTIERS IN MEDICINE (2020)
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients
Umberto Malapelle et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Primary Melanoma of the Lung: A Systematic Review
Panagiotis Paliogiannis et al.
MEDICINA-LITHUANIA (2020)
Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review
Jiarui Li et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Rong Zhou et al.
CLINICAL CANCER RESEARCH (2019)
miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy
Huan Tang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma
Antoine Moya-Plana et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy
Longwen Xu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Felicity Newel et al.
NATURE COMMUNICATIONS (2019)
Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy
Natsuko Iga et al.
CANCER SCIENCE (2019)
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
Xinan Sheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation
Lei Miao et al.
NATURE BIOTECHNOLOGY (2019)
BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas
Maria Colombino et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
Nicolas Dumaz et al.
CANCERS (2019)
MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways
Meng Ma et al.
THERANOSTICS (2019)
Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients
ChuanLiang Cui et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
Omid Hamid et al.
BRITISH JOURNAL OF CANCER (2018)
Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches
Giuseppe Palmieri et al.
CURRENT ONCOLOGY REPORTS (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
Claire Mignard et al.
JOURNAL OF ONCOLOGY (2018)
Combatting mucosal melanoma: recent advances and future perspectives
Helen Tyrrell et al.
MELANOMA MANAGEMENT (2018)
The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients
B. Lian et al.
ANNALS OF ONCOLOGY (2017)
Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma
Markus V. Heppt et al.
EUROPEAN JOURNAL OF CANCER (2017)
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P. D'Angelo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinics, prognosis and new therapeutic options in patients with mucosal melanoma A retrospective analysis of 75 patients
Tim Schaefer et al.
MEDICINE (2017)
Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma
Jennifer D. Hintzsche et al.
MELANOMA RESEARCH (2017)
Whole-genome landscapes of major melanoma subtypes
Nicholas K. Hayward et al.
NATURE (2017)
BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma
X. Bai et al.
NEOPLASMA (2017)
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial
J. Guo et al.
ANNALS OF ONCOLOGY (2017)
Mucosal melanoma of the head and neck
Paolo Antonio Ascierto et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
The Efficacy of Anti-PD-1 Agents in Acral and Mucosal Melanoma
Alexander N. Shoushtari et al.
CANCER (2016)
RASopathy Gene Mutations in Melanoma
Ruth Halaban et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Epidemiology of genitourinary melanoma in the United States: 1992 through 2012
Ritva Vyas et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis
Deborah Kuk et al.
ONCOLOGIST (2016)
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Richard D. Carvajal et al.
CLINICAL CANCER RESEARCH (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Melanoma of the Vulva and Vagina: Principles of Staging and Their Relevance to Management Based on a Clinicopathologic Analysis of 85 Cases
Susan Seifried et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Moriah H. Nissan et al.
CANCER RESEARCH (2014)
Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma
Michele Del Vecchio et al.
EUROPEAN JOURNAL OF CANCER (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma
Marliese Alexander et al.
MEDICAL JOURNAL OF AUSTRALIA (2014)
Unexpected Distribution of cKIT and BRAF Mutations among Southern Italian Patients with Sinonasal Melanoma
Maria Colombino et al.
DERMATOLOGY (2013)
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma
Simon J. Furney et al.
JOURNAL OF PATHOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Ipilimumab for Patients With Advanced Mucosal Melanoma
Michael A. Postow et al.
ONCOLOGIST (2013)
Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations
Nicola L. Schoenewolf et al.
EUROPEAN JOURNAL OF CANCER (2012)
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
Jin Hyun Cho et al.
INVESTIGATIONAL NEW DRUGS (2012)
Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity
Richard D. Carvajal et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management
Michael A. Postow et al.
CURRENT ONCOLOGY REPORTS (2012)
Noncutaneous Melanoma Have Distinct Features from Each Other and Cutaneous Melanoma
Faruk Tas et al.
ONCOLOGY (2011)
Treatment of Primary Melanoma of the Lung Monitored by 5-S-Cysteinyldopa Levels
Kei Shikuma et al.
ANNALS OF THORACIC SURGERY (2009)
Endoscopic Resection of Sinonasal Cancers With and Without Craniotomy Oncologic Results
Ehab Hanna et al.
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY (2009)
KIT Gene Mutations and Copy Number in Melanoma Subtypes
Carol Beadling et al.
CLINICAL CANCER RESEARCH (2008)
What is the role of radiotherapy in the treatment of mucosal melanoma of the head and neck?
Marco Krengli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Oral malignant melanoma: a review of the literature
Felice Femiano et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2008)
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy
Benjamin F. Johnson et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Primary mucosal melanoma of head and neck: Prognostic value of clear margins
N Penel et al.
LARYNGOSCOPE (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Overproduction of VEGF165 concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling
J Graells et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Determinants of BRAF mutations in primary melanomas
JL Maldonado et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Development of melanocyte precursors from the vertebrate neural crest
E Dupin et al.
ONCOGENE (2003)
Sinonasal tract and nasopharyngeal melanomas - A clinicopathologic study of 115 cases with a proposed staging system
LDR Thompson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Primary mucosal malignant melanoma of the head and neck
SG Patel et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2002)